» Articles » PMID: 39941499

The Correlation Between Meibomian Gland Dysfunction and Aniridia-Associated Keratopathy: A Prospective Analysis

Overview
Journal J Clin Med
Specialty General Medicine
Date 2025 Feb 13
PMID 39941499
Authors
Affiliations
Soon will be listed here.
Abstract

: Aniridia is a rare congenital disorder characterized by structural and functional abnormalities in ocular development due to PAX6 haploinsufficiency, leading to complications such as aniridia-associated keratopathy (AAK). Meibomian gland dysfunction (MGD), a prevalent yet underexplored condition in aniridia, exacerbates tear film instability and chronic ocular surface inflammation, contributing to AAK progression. This study investigates the relationship between MGD severity and AAK in individuals with aniridia. : This prospective randomized study included 113 participants (53 with aniridia and 60 controls). Comprehensive ophthalmic evaluations, including noninvasive meibography, were performed. The MGD severity was assessed using a standardized meiboscore scale, while the AAK severity was classified according to established clinical grading criteria. Statistical analyses, including Spearman's correlation and chi-squared tests, were used to evaluate the relationships among MGD, AAK, and visual acuity. : MGD was significantly more prevalent and severe in the aniridia group compared to controls ( < 0.00001). A strong positive correlation was observed between MGD severity and AAK grade (r = 0.72, < 0.00001), with both conditions associated with reduced best-corrected visual acuity (BCVA; r = -0.80 and -0.86, respectively, < 0.0001). Age was positively correlated with MGD (r = 0.47, = 0.0004) and AAK (r = 0.34, = 0.0123), with gender-specific trends observed in females. : MGD significantly contributes to AAK progression and visual impairment in aniridia. Meibography offers valuable insights into MGD severity, supporting early diagnosis and targeted interventions. Addressing MGD through tailored therapies could mitigate AAK progression and improve visual outcomes in this challenging condition.

References
1.
Kim C, Carter S, Kim C, Shooshani T, Mehta U, Marshall K . Risk Factors for Meibomian Gland Disease Assessed by Meibography. Clin Ophthalmol. 2023; 17:3331-3339. PMC: 10627068. DOI: 10.2147/OPTH.S428468. View

2.
Latta L, Figueiredo F, Ashery-Padan R, Collinson J, Daniels J, Ferrari S . Pathophysiology of aniridia-associated keratopathy: Developmental aspects and unanswered questions. Ocul Surf. 2021; 22:245-266. DOI: 10.1016/j.jtos.2021.09.001. View

3.
Swiderska K, Read M, Blackie C, Maldonado-Codina C, Morgan P . Latest developments in meibography: A review. Ocul Surf. 2022; 25:119-128. DOI: 10.1016/j.jtos.2022.06.002. View

4.
Alvarez de Toledo Elizalde J, Lopez Garcia S, Benitez Del Castillo J, Duran de la Colina J, Gris Castejon O, Celis Sanchez J . Aniridia and the ocular surface: Medical and surgical problems and solutions. Arch Soc Esp Oftalmol (Engl Ed). 2021; 96 Suppl 1:15-37. DOI: 10.1016/j.oftale.2021.04.003. View

5.
Lagali N, Wowra B, Fries F, Latta L, Moslemani K, Utheim T . Early phenotypic features of aniridia-associated keratopathy and association with PAX6 coding mutations. Ocul Surf. 2019; 18(1):130-140. DOI: 10.1016/j.jtos.2019.11.002. View